Favorable Press Coverage Somewhat Unlikely to Impact Chemours Company (The) (CC) Stock Price
Media headlines about Chemours Company (The) (NYSE:CC) have been trending positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chemours Company (The) earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned news articles about the specialty chemicals company an impact score of 46.8544897456537 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Weber Alan W Has $758000 Position in Chemours Company (The) (NYSE:CC) (campdesrecrues.com)
- Trading summary of Watch List stock – The Chemours Company (CC) (overnewsmagazine.com)
- Chemours Company (The) (NYSE:CC) Earns Buy Rating from Argus (expressnewsline.com)
- Uptrend Call Working As Chemours Co Stock Rises 13.2% (CC) (mysmartrend.com)
- Old Mutual Global Investors (uk) Ltd. Marginally Raises Its Holdings in Chemours Company (The) (CC) – Highlight Press (highlightpress.com)
Several equities research analysts recently weighed in on the stock. BidaskClub cut shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Saturday, June 17th. Citigroup Inc. reaffirmed a “neutral” rating and set a $40.00 price objective (up previously from $34.00) on shares of Chemours Company (The) in a research report on Friday, April 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $50.00 price objective (up previously from $48.00) on shares of Chemours Company (The) in a research report on Thursday, July 13th. UBS AG raised shares of Chemours Company (The) from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $36.00 to $50.00 in a research report on Monday. Finally, Susquehanna Bancshares Inc upped their price objective on shares of Chemours Company (The) from $45.00 to $55.00 and gave the stock a “positive” rating in a research report on Monday, May 15th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $51.50.
Chemours Company (NYSE:CC) traded up 4.35% on Friday, hitting $46.34. 1,938,391 shares of the stock were exchanged. The company has a 50-day moving average price of $43.25 and a 200-day moving average price of $37.90. Chemours Company has a 52-week low of $11.09 and a 52-week high of $51.51. The firm has a market cap of $8.56 billion, a PE ratio of 30.33 and a beta of 3.63.
Chemours Company (The) (NYSE:CC) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the firm earned $0.27 earnings per share. Chemours Company (The)’s revenue was up 14.8% on a year-over-year basis. On average, equities research analysts anticipate that Chemours Company will post $3.51 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 17th will be given a $0.03 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $0.12 dividend on an annualized basis and a yield of 0.26%. Chemours Company (The)’s payout ratio is 8.11%.
In related news, VP Erich Parker sold 4,908 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total value of $223,461.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul Kirsch sold 19,036 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $41.42, for a total value of $788,471.12. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.
Chemours Company (The) Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.